HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells - Summary - MDSpire

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

  • By

  • Cansu Yerinde

  • Jacqueline Keye

  • Hsiang-Jung Hsiao

  • Sibel Durlanik

  • Inka Freise

  • Franziska Nowak

  • Marilena Letizia

  • Stephan Schlickeiser

  • Benedikt Obermayer

  • Adrian Huck

  • Marie Friedrich

  • Hao Wu

  • Désirée Kunkel

  • Anja A. Kühl

  • Sebastian Bauer

  • Andreas Thiel

  • Ahmed N. Hegazy

  • Britta Siegmund

  • Rainer Glauben

  • Carl Weidinger

  • May 12, 2026

  • 0 min

Share

Objective:

To investigate the role of HDAC7 in the differentiation and functionality of peripheral CD8+ T cells in anti-viral and anti-tumor immunity, highlighting its significance in T cell responses.

Key Findings:
  • HDAC7 deficiency leads to upregulation of immune checkpoint molecules and increased apoptosis in CD8+ T cells, potentially through MEF2D-dependent pathways.
  • Absence of HDAC7 disrupts glutamine homeostasis and impairs metabolic fitness of CD8+ T cells, affecting their functionality.
  • HDAC7 is essential for effective anti-tumor responses in lymphoma models and for memory recall in viral infections, indicating its therapeutic potential.
Interpretation:

HDAC7 is a crucial regulator of CD8+ T cell functionality, influencing apoptosis, metabolic fitness, and immune responses against tumors and viruses, with implications for immunotherapy.

Limitations:
  • Study primarily conducted in murine models, which may not fully translate to human CD8+ T cell responses, necessitating caution in interpretation.
  • Further research needed to elucidate the specific molecular mechanisms by which HDAC7 regulates T cell functions, particularly in human contexts.
Conclusion:

HDAC7 plays a pivotal role in managing CD8+ T cell exhaustion and apoptosis, thereby influencing anti-tumor and anti-viral immunity, highlighting its potential as a therapeutic target.

Original Source(s)

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

  • by Cansu Yerinde, Jacqueline Keye, Hsiang-Jung Hsiao, Sibel Durlanik, Inka Freise, Franziska Nowak, Marilena Letizia, Stephan Schlickeiser, Benedikt Obermayer, Adrian Huck, Marie Friedrich, Hao Wu, Désirée Kunkel, Anja A. Kühl, Sebastian Bauer, Andreas Thiel, Ahmed N. Hegazy, Britta Siegmund, Rainer Glauben, Carl Weidinger

  • May 12, 2026

Related Content

Case Report: Fibrin-associated large B-cell lymphoma developing within a cystic lesion of the adrenal gland: unexpected guest

Research Leaders Across New York State Form Empire State Cellular Therapy Consortium

To expand on early progress in the emerging field of cell and gene therapy, five research centers across New York State are collaborating to develop new cell therapies for cancer and other diseases.

  • by

  • July 29, 2025

  • 7 min
Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma